The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Nikitin E.A.
Botkin Moscow City Clinical Hospital;
Russian Medical Academy of Continuous Professional Education
Atrial fibrillation and bleeding as complications of targeted therapy in chronic lymphocytic leukemia with impact on cardiovascular mortality
Journal: Russian Cardiology Bulletin. 2024;19(3): 16‑25
Views: 462
Downloaded: 36
To cite this article:
Ergasheva UP, Panchenko EP, Nikitin EA. Atrial fibrillation and bleeding as complications of targeted therapy in chronic lymphocytic leukemia with impact on cardiovascular mortality. Russian Cardiology Bulletin.
2024;19(3):16‑25. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20241903116
Bruton tyrosine kinase inhibitors have dramatically changed the management of patients with chronic lymphocytic leukemia over the past decade. Despite clear efficacy of this class in the treatment of chronic lymphocytic leukemia, cardiovascular complications of Bruton tyrosine kinase inhibitors remain one of the most common reasons for discontinuation of anticancer therapy. This review focuses on cardiovascular complications of Bruton tyrosine kinase inhibitors and recommendations for the management of patients with chronic lymphocytic leukemia undergoing anticancer therapy.
Keywords:
Authors:
Nikitin E.A.
Botkin Moscow City Clinical Hospital;
Russian Medical Academy of Continuous Professional Education
Received:
20.06.2024
Accepted:
24.06.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.